OGT’s Genefficiency™ genomic services and CytoSure™ cytogenetics research products showcased at ASHG
Visitors to the 59th annual meeting of the American Society of Human Genetics in Honolulu,
Hawaii, will have ample opportunity to see the latest state-of-the-art solutions from Oxford Gene
Technology (OGT) – ranging from disease research services to cytogenetics research products.
As well as having a strong presence in the exhibitors’ hall, OGT will be showcasing its
comprehensive solutions for disease and cytogenetics research at a satellite meeting held in
room 325 of the Convention Center at 12 noon on Thursday October 22nd, entitled ‘From disease
to cytogenetics research – an integrated CNV analysis platform from Oxford Gene Technology’.
In the meeting, Dr Jonathan Sebat, Associate Professor of Human Genetics at Cold Spring
Harbor Laboratory, will review some of the challenges in cohort studies, while Dr David Ledbetter,
Professor of Human Genetics at Emory University School of Medicine, will elaborate on some of
the considerations in taking aCGH to the clinic, including the ISCA Consortium and Public
Database.
Dr John Anson, R&D Director at OGT, commented: “We are delighted to welcome two
distinguished guest speakers to the podium, who will be discussing developments from disease
to cytogenetics research. We will outline how OGT has aligned its portfolio of products and
services to support these efforts.”
OGT’s Genefficiency™ genomic services and CytoSure™ cytogenetic aCGH products offer an
integrated and standardised solution for array-based disease association studies and
cytogenetics research.
OGT 483-09/2
Go to http://www.ogt.co.uk/genefficiency for more details and to register for the satellite meeting,
or visit OGT at stand 118 to see the very latest technology and services available for CNV
analysis.
Notes for editors:
About Oxford Gene Technology:
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative clinical genetics and diagnostic solutions to advance molecular medicine. www.ogt.co.uk.
Clinical & Genomic Solutions: OGT’s Genefficiency™ is a unique combination of world-leading platforms, people, processing power and performance synchronised to deliver rapid, high quality genomic data to customers worldwide. The OGT CytoSure™ cytogenetics array, labelling and interpretation software products provide a complete solution for the detection of chromosomal abnormalities. Together, Genefficiency and CytoSure offer a unique, standardised and integrated solution for cytogenetics research.
Biomarker Discovery: OGT has a proven pedigree in genomic technology, which, together with the experience gained through the purchase of Sense Proteomics in 2009, enables OGT to develop highly specific customised genomic and proteomic biomarker panels for cancer and other diseases. OGT develops these for clinical screening and companion diagnostics requirements, both for direct sale and also for collaboration with partner companies.
CytoSure™: For research use only
This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.